Technology Opportunities & Ventures
While focus is on header menu items,
press the down arrow to open sub-menu.
press the down arrow to open sub-menu.
2023
Active
Principal Investigators: Jun Wang, PhD
Remunix is developing novel therapeutics for the treatment of autoimmune diseases. Their approach is based on new insights into the fundamental biology of immune cell activation and checkpoints. They are pioneering a new class of antibody-based drugs that will safely and selectively attenuate the autoimmune response.